Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

46,012 stories, page 716 of 767

Advanced search

🇺🇰Jul 19, 2022Industrygenialcompliance.comTier 3 · Secondary coverage

Genial's White Paper on Risk - Genial

Genial Genetics (Pathozoom AI)Original source

🌍Jun 23, 2022Industryq32bio.comTier 1 · Company source

Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097

Q32 BioOriginal source

🌍Jun 21, 2022Industryonkuretherapeutics.comTier 1 · Company source

OnKure Therapeutics Appoints Kevin S. Litwiler, Ph.D., as Senior Vice President of DMPK and Clinical Pharmacology

OnKure TherapeuticsOriginal source

🌍Jun 8, 2022Industryq32bio.comTier 1 · Company source

Shelia Violette, Founder and Chief Scientific Officer of Q32 Bio, to Present at the Keystone Symposia “Resolution of Inflammation” Conference

Q32 BioOriginal source

🌍Jun 7, 2022Industryblueprintgenetics.comTier 1 · Company source

New research collaboration helps shorten the path to diagnosis for rare disease patients through analysis of biobank samples

Blueprint Genetics (Quest Diagnostics)Original source

🌍Jun 2, 2022Industryonkuretherapeutics.comTier 1 · Company source

OnKure Therapeutics Announces First Patient Dosed in the Phase 1b/2 Nautilus Trial of OKI-179 in Combination with Binimetinib in Patients with Advanced NRAS-Mutated Melanoma

OnKure TherapeuticsOriginal source

🇺🇸Jun 1, 2022Researchforesitecapital.comTier 2 · Direct publisher

Thoughts on the Affinivax Acquisition

Foresite CapitalOriginal source

🌍May 31, 2022Industrycerbios.swissTier 3 · Secondary coverage

New additional R&D laboratory unit

Cerbios-Pharma SAOriginal source

🇵🇹May 26, 2022Regulatoryapifarma.ptTier 1 · Regulatory source

Comentário em Formação e Educação por Apifarma - Contactos E Localização - Apifarma

APIFARMA PortugalOriginal source

🌍May 25, 2022Industryblueprintgenetics.comTier 1 · Company source

Blueprint Genetics, a quality leader in genetic testing, embraces new EU regulation (IVDR)

Blueprint Genetics (Quest Diagnostics)Original source

🇵🇹May 23, 2022Regulatoryapifarma.ptTier 1 · Regulatory source

Comentário em Áreas de intervenção por Novo Membro – Apifarma - Informar - Portal de Cursos de Formação Profissional

APIFARMA PortugalOriginal source

🇺🇸May 20, 2022Industrysirnaomics.comTier 1 · Company source

Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit

SirnaomicsOriginal source

🌍Apr 25, 2022Industrycooperpharma.maTier 1 · Company source

Actions terrain auprès des pharmaciens et des médecins

Cooper Pharma MoroccoOriginal source

🌍Apr 25, 2022Industrycooperpharma.maTier 1 · Company source

Produits soutenus par des unités opérationnelles et des réseaux de médecins spécialisées

Cooper Pharma MoroccoOriginal source

🌍Apr 25, 2022Industryonkuretherapeutics.comTier 1 · Company source

OnKure Therapeutics Expands Boulder Footprint with the Opening of a New Research Laboratory

OnKure TherapeuticsOriginal source

🇺🇰Apr 21, 2022Industrygenialcompliance.comTier 3 · Secondary coverage

Top 10 Most Common Risks of Homegrown Document Control & Compliance Solutions - Genial

Genial Genetics (Pathozoom AI)Original source

🌍Apr 9, 2022Industryonkuretherapeutics.comTier 1 · Company source

OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a Late-Breaking Session at AACR

OnKure TherapeuticsOriginal source

🇨🇦Apr 6, 2022Researchucalgary.caTier 2 · Direct publisher

CMF FILMMAKER IN RESIDENCE 2022

University of CalgaryOriginal source

🇺🇸Mar 30, 2022Industrysirnaomics.comTier 1 · Company source

RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines | Sirnaomics

SirnaomicsOriginal source

🌍Mar 23, 2022Industryomniab.comTier 1 · Company source

Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II

OmniAbOriginal source

🇩🇰Mar 18, 2022Industryserviersymphogen.comTier 3 · Secondary coverage

Scientist for In Vivo Pharmacology

SymphogenOriginal source

🌍Mar 16, 2022Industryan2therapeutics.comTier 1 · Company source

AN2 Therapeutics Appoints Dr. Mel Spigelman, M.D. to its Board of Directors

AN2 TherapeuticsOriginal source

🇺🇸Mar 15, 2022Industrysirnaomics.comTier 1 · Company source

Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress

SirnaomicsOriginal source

🇺🇸Mar 12, 2022Industrydyne-tx.comTier 1 · Company source

rare disease day video presentation

Dyne TherapeuticsOriginal source

🌍Mar 9, 2022Industryonkuretherapeutics.comTier 1 · Company source

OnKure Therapeutics to Present Late-Breaking Preclinical Data on OKI-179 at the AACR Annual Meeting 2022

OnKure TherapeuticsOriginal source

🇺🇸Mar 8, 2022CDMOnoramco.comTier 2 · Direct publisher

Noramco Celebrates Diversity and International Women’s Day

NoramcoOriginal source

🇫🇮Mar 4, 2022Researchhelsinki.fiTier 2 · Direct publisher

Ukrainan sota - yliopiston suositukset

Helsinki University ResearchOriginal source

🇺🇰Mar 3, 2022Industrygenialcompliance.comTier 3 · Secondary coverage

Genial and Cirdan to offer a genomics enabled LIS solution to healthcare customers globally - Genial

Genial Genetics (Pathozoom AI)Original source

🌍Feb 16, 2022Industryan2therapeutics.comTier 1 · Company source

AN2 Therapeutics Announces Epetraborole Granted Orphan Drug Designation in the U.S. for the Treatment of Infections Caused by Non-Tuberculous Mycobacteria

AN2 TherapeuticsOriginal source

🌍Feb 10, 2022Industryan2therapeutics.comTier 1 · Company source

AN2 Therapeutics Reports Phase 1b Data for Oral Epetraborole

AN2 TherapeuticsOriginal source

🌍Feb 8, 2022Industryonkuretherapeutics.comTier 1 · Company source

OnKure Therapeutics Appoints Jason Leverone, CPA, as Chief Financial Officer

OnKure TherapeuticsOriginal source

🇧🇪Feb 5, 2022Industryucb.comTier 1 · Company source

Disposals of own shares

UCB PharmaOriginal source

🇧🇪Feb 4, 2022Industryucb.comTier 1 · Company source

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

UCB PharmaOriginal source

🇧🇪Feb 3, 2022Industryucb.comTier 1 · Company source

Transparency notification FMR LLC.

UCB PharmaOriginal source

🇺🇸Feb 3, 2022Researchforesitecapital.comTier 2 · Direct publisher

Welcoming the Foresite Fellows

Foresite CapitalOriginal source

🇧🇪Feb 2, 2022Industryucb.comTier 1 · Company source

UCB Receives Positive CHMP Opinion Recommending Approval of BRIVIACT[®] (brivaracetam) and VIMPAT[®] (lacosamide) in the EU for Partial-Onset Seizures in Pediatric Patients From Two to Four Years

UCB PharmaOriginal source

🇧🇪Feb 2, 2022Industryucb.comTier 1 · Company source

UCB Commences Tender Offer to Acquire Zogenix, Inc.

UCB PharmaOriginal source

🇧🇪Jan 29, 2022Industryucb.comTier 1 · Company source

Disposals of own shares

UCB PharmaOriginal source

🇧🇪Jan 24, 2022Industryucb.comTier 1 · Company source

BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma

UCB PharmaOriginal source

🇧🇪Jan 22, 2022Industryucb.comTier 1 · Company source

Disposals of own shares

UCB PharmaOriginal source

🇧🇪Jan 21, 2022Industryucb.comTier 1 · Company source

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study

UCB PharmaOriginal source

🌍Jan 20, 2022Industryan2therapeutics.comTier 1 · Company source

AN2 Therapeutics Provides Regulatory Update

AN2 TherapeuticsOriginal source

🇧🇪Jan 19, 2022Industryucb.comTier 1 · Company source

UCB to acquire Zogenix

UCB PharmaOriginal source

🌍Jan 18, 2022Industryonkuretherapeutics.comTier 1 · Company source

OnKure Therapeutics Appoints Nicholas A. Saccomano, Ph.D., to its Board of Directors

OnKure TherapeuticsOriginal source

🌍Jan 7, 2022Industryan2therapeutics.comTier 1 · Company source

AN2 Therapeutics Closed $80 Million Series B Financing

AN2 TherapeuticsOriginal source

🇺🇸Dec 30, 2021Industrysirnaomics.comTier 1 · Company source

Sirnaomics Ltd. Listed on Main Board of HKEX | Sirnaomics

SirnaomicsOriginal source

🌍Dec 28, 2021Industryproqr.comTier 1 · Company source

Fall Eye on the Future Forum (EFF) Summit 2020

ProQROriginal source

🌍Dec 28, 2021Industryproqr.comTier 1 · Company source

American Academy of Optometry (AAOpt) Annual Meeting 2020

ProQROriginal source

🌍Dec 28, 2021Industryproqr.comTier 1 · Company source

Expert Perspectives Series – Usher Syndrome and Retinitis Pigmentosa

ProQROriginal source

🌍Dec 28, 2021Industryproqr.comTier 1 · Company source

ProQR Top-line results Phase 1/2 trial of sepofarsen in LCA10 patients

ProQROriginal source

🌍Dec 28, 2021Industryproqr.comTier 1 · Company source

Expert Perspectives Series – LCA10 and sepofarsen

ProQROriginal source

🌍Dec 28, 2021Industryproqr.comTier 1 · Company source

American Academy of Ophthalmology (AAO) Annual Meeting 2020

ProQROriginal source

🌍Dec 28, 2021Industryproqr.comTier 1 · Company source

American Academy of Ophthalmology (AAO) Annual Meeting 2021

ProQROriginal source

🌍Dec 28, 2021Industryproqr.comTier 1 · Company source

The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2021

ProQROriginal source

🌍Dec 22, 2021Industryomniab.comTier 1 · Company source

Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy

OmniAbOriginal source

🌍Dec 14, 2021Industryonkuretherapeutics.comTier 1 · Company source

OnKure Therapeutics Announces Positive Topline First-in-Human Phase 1 Results for OKI-179

OnKure TherapeuticsOriginal source

🇺🇸Dec 3, 2021CDMOnoramco.comTier 2 · Direct publisher

Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient

NoramcoOriginal source

🇺🇰Nov 12, 2021Industrygenialcompliance.comTier 3 · Secondary coverage

Customer renewal: Nonacus Ltd - Genial

Genial Genetics (Pathozoom AI)Original source

🌍Nov 9, 2021Industryonkuretherapeutics.comTier 1 · Company source

OnKure Therapeutics Appoints Mark L. Boys, Ph.D., as Vice President of Discovery Chemistry

OnKure TherapeuticsOriginal source

🌍Nov 9, 2021Industryomniab.comTier 1 · Company source

Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company

OmniAbOriginal source